Loading…
Affordable Biologics for Consumers Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,722 other S bills in the 110th — cohort avg 42d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (43)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2009 · second_quarter · Pharmacy
Access to Life-Saving Medicine Act (H.R. 1038 & S. 623), Affordable Biologics for Consumers Act (S. 1505), Biologics Price Competition and Innovation Act of 2007 (S. 1695), Consumer Food Safety Act of 2008 (H.R. 3624), Fair Prescription Drug Competition Act (H.R. 806 & S. 438), Food and Drug Import Safety Act of 2007 (H.R. 3610, The Pathway for Biologics Act (H.R. 5629), The Patient Protection and Innovative Biologic Medicines Act (H.R. 1956).
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
HR 4703, S 2467, HR 4991 - Vaccine Shortage preparedness Act of 2008 S 2464, HR 4992, HR 4704 - A bill to amend title XVIII of the Social Security Act to provide for coverage of federally recommended vaccines under Medicare Part B S 2465 - Vaccines for Children Access Act of 2008 HR 2 - Children's Health Insurance Program Reauthorization Act of 2009 S 75 - Generics First Act 2009 S 80 - Importation of Prescription Drugs S 301 - Physician Payments Sunshine Act of 2009 HR 276 - Proper Disposal of Unused Pharmaceuticals HR 5839 - Safeguarding America's Pharmaceuticals Act of 2008 S 3408 - Comparative Effectiveness Research Act of 2008 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 4705 HR 4993, S 2466 - Vaccines for the uninsured Adult Act of 2008 S 2467 - Vaccine shortage preparedness Act of 2008 S 3678 - /PL 109-417 All pandemic and all-hazards act - Section 317 program issues HR 970 and S 1378 - Dextromethorphan Distribution Act of 2007 S 103 - Combat Meth Act of 2005 HR 2207 - Agricultural Disaster Assistance and Western States Emergency - Unfinished business Appropriations Act of 2007 HR 1908 and S 1710 Patent Reform Act of 2007 HR 1 - Implementing the 9/11 Commission recommendations Act of 2007 HR 3162 - Children's Health and Medicare Protection Act of 2007 S 1505 - Affordable Biologics for Consumers Act S 1695 - Biologics Price Competition and Innovation Act of 2007 HR 1956 - Patent Protection and Innovative Biologic Medicines Act of 2007 HR 1038, S623 - Access to Life-Saving Medicine Act HR 4083 - Non-prescription Drug Modernization Act of 2007 HR 1308 - Legal Immigrant Children's Health Improvement Act of 2007 HR 5629 - Pathway for Biosimilars Act HR 1427 - To amend the Public Health Service Act to provide for the licensing of biosimilar and biogeneric biological products, and for other purposes S 726 - A bill to amend the Public Health Service Act to provide for the licensing of biosimilar and biogeneric biological products, and for other purposes HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes Comparative Effectiveness Research Public Health Service Act Drug Importation Gene Therapy Direct to Consumer Advertising Drug Safety Legislation Global Hypertension
Client expense: $1,347,134 · Firm income: Not reported
2008 · second_quarter · Medicare/Medicaid
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · second_quarter · Copyright/Patent/Trademark
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Client expense: $2,860,000 · Firm income: Not reported
2008 · second_quarter · Economics/Economic Development
Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · second_quarter · Medical/Disease Research/Clinical Labs
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Agency for International Development (USAID)
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · second_quarter · Medical/Disease Research/Clinical Labs
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · second_quarter · Medicare/Medicaid
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · second_quarter · Copyright/Patent/Trademark
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · second_quarter · Economics/Economic Development
Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · fourth_quarter · Pharmacy
S. 877, Controlling the Abuse of Prescriptions Act of 2007 Drug importation H. R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H. R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics H. R. 5629, Pathway for Biosimilars Act S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 623, Access to Life-Saving Medicine Act, follow-on biologics
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE
2008 · fourth_quarter · Medical/Disease Research/Clinical Labs
S. 623 Access to Lifesaving Medicine Act H.R. 1038 Access to Lifesaving Medicine Act H.R. 1956 Patient Protection and Innovative Biologic Medicine Act of 2007 S. 1695 Biologics Price Competition and Innovation Act of 2007 S. 1505 Affordable Biologics for Consumer Act H.R. 5629 Pathway for Biosimilars Act
Client expense: $2,000,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2008 · fourth_quarter · Medical/Disease Research/Clinical Labs
S. 623 Access to Lifesaving Medicine Act H.R. 1038 Access to Lifesaving Medicine Act H.R. 1956 Patient Protection and Innovative Biologic Medicine Act of 2007 S. 1695 Biologics Price Competition and Innovation Act of 2007 S. 1505 Affordable Biologics for Consumer Act H.R. 5629 Pathway for Biosimilars Act
Client expense: $2,000,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2008 · fourth_quarter · Pharmacy
Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695). Food and Drug Administration Amendents Act of 2007 (H.R. 3580) Counterfeit Drugs/Import safety/Pedigree Electronic prescribing (including H.R. 6331, S. 2408, and H.R. 4296) Prescription drug importation/re-importation Average Manufacturers Price/AMP
Client expense: Not reported · Firm income: $40,000
Government targets: Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Health Issues
Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695). Food and Drug Administration Amendents Act of 2007 (H.R. 3580) Counterfeit Drugs/Import safety/Pedigree Electronic prescribing (including H.R. 6331, S. 2408, and H.R. 4296) Prescription drug importation/re-importation Average Manufacturers Price/AMP
Client expense: Not reported · Firm income: $40,000
Government targets: Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Pharmacy
-Advocated for cost containment policies including generic access, e-prescribing, and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace (including but not limited to HR 5629, HR 1956, S 1505, and S. 1695).
Client expense: Not reported · Firm income: $30,000
Government targets: Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Medicare/Medicaid
-Advocated for cost containment policies including generic access, e-prescribing, and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace (including but not limited to HR 5629, HR 1956, S 1505, and S. 1695).
Client expense: Not reported · Firm income: $30,000
Government targets: Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Health Issues
-Advocated for cost containment policies including generic access, e-prescribing, and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace (including but not limited to HR 5629, HR 1956, S 1505, and S. 1695).
Client expense: Not reported · Firm income: $30,000
Government targets: Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Pharmacy
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promote competition in the pharmaceutical marketplace, including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695; advocate for cost containment policies related to electronic prescriptions including but not limited H.R. 6631, S. 2408, H.R. 4296.
Client expense: Not reported · Firm income: $40,000
Government targets: Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Health Issues
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promote competition in the pharmaceutical marketplace, including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695; advocate for cost containment policies related to electronic prescriptions including but not limited H.R. 6631, S. 2408, H.R. 4296.
Client expense: Not reported · Firm income: $40,000
Government targets: Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Health Issues
Advocate for cost containment policies related to electronic prescriptions, comparative effectiveness, and advocate for policies on broader health care reform initiatives (including but not limited to H.R. 6631, S. 2408, H.R. 4296, S. 334). Advocate for cost containment policies related to the creation of a regulatory pathway for generic biologic medications (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695).
Client expense: Not reported · Firm income: $30,000
Government targets: Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Pharmacy
-Advocate for cost containment policies related to the creation of a regulatory pathway for generic biologic medications (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695).
Client expense: Not reported · Firm income: $30,000
Government targets: Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Health Issues
Advocate for initiatives designed to improve safety, enhance quality and constrain costs through generic utilization and the use of electronic prescribing (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695, H.R. 6631, S. 2408, and H.R. 4296)
Client expense: Not reported · Firm income: $60,000
Government targets: Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Medicare/Medicaid
Advocate for initiatives designed to improve safety, enhance quality and constrain costs through generic utilization and the use of electronic prescribing (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695, H.R. 6631, S. 2408, and H.R. 4296)
Client expense: Not reported · Firm income: $60,000
Government targets: Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Pharmacy
Advocate for initiatives designed to improve safety, enhance quality and constrain costs through generic utilization and the use of electronic prescribing (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695, H.R. 6631, S. 2408, and H.R. 4296)
Client expense: Not reported · Firm income: $60,000
Government targets: Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Health Issues
General diabetes legislative initiatives; Food and Drug Globalization Inspection bills; Uninsured and health reform issues; HR1038, HR5629, S1505, S1695 follow on biologic bills; HR6898 Health Information Technology; HR1424 Mental Health Equity Act; S1389, HR1113 Inflammatory Bowel Disease Research Act; HR3195 ADA Amendment Act; Evidence Based Medicine and Quality issues; general coverage issues, S3230 Labor HHS Appropriations, S.2162, HR2922, S3408, S3396
Client expense: $260,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), SENATE
2008 · fourth_quarter · Copyright/Patent/Trademark
HR1038, HR5629, S1505, S1695 Follow On Biologics; S3325, S4364, S3600 Patent and Intellectual Property enforcement and reform bills
Client expense: $260,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), SENATE
2008 · fourth_quarter · Copyright/Patent/Trademark
H.R.1038, Access to Life-Saving Medicine Act; H.R.1908, Patent Reform Act of 2007; H.R.5629, Pathway for Biosimilars Act; S.316, Preserve Access to Affordable Generics Act; S.623, Access to Life-Saving Medicine Act; S.1082, Food and Drug Administration Revitalization Act; S.1145, Patent Reform Act of 2007; S.1505, Affordable Biologics for Consumers Act; S.3463, A bill to amend the trade Act of 1974; S.3600, A bill to amend Title 35 US Code. Legislative proposals effecting US patent system: H.R.1908, Patent Reform Act of 2007; S.1145, Patent Reform Act of 2007; S.3463, A bill to amend the Trade Act of 1974 to improve the international protection and enforcement of intellectual property rights, and for other purposes; S.3600, A bill to amend title 35 US Code, to provide for patent reforms. Legislative proposals regarding follow-on biologics: H.R.1038, Access to Life-Saving Medicine Act; H.R.5629, Pathway for Biosimilars Act; S.623, Access to Life-Saving Medicine Act; S.1082, Food and Drug Administration Revitalization Act; S.1505, Affordable Biologics for Consumers Act. Legislative proposals regarding brand-generic drug firm agreements: S.316, Preserve Access to Affordable Generics Act.
Client expense: $520,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Copyright/Patent/Trademark
S. 1145, Patent Reform Act of 2007 HR. 1908, Patent Reform Act of 2007 HR. 1038, Access to Life-Saving Medicine Act, Follow-on Biologics HR. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, Follow-on Biologics HR. 5629, Pathway for Biosimilars Act S. 1505, Affordable Biologic for Consumers Act of 2007, follow-on Biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on Biologics S. 623, Access to Life-Saving Medicine Act, Follow-on biologics S. 3600 Patent Reform Act of 2008
Client expense: $658,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2008 · fourth_quarter · Pharmacy
H.R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, Follow-on biologics H.R. 5629, Pathway for Biosimilars Act S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics S.1695, Biologics Price Competition and Innovation Act of 2007, Follow-on Biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 623, Access to Life-Saving Medicine Act, follow-on biologics Neglected Disease Issues Issues related to Drug Safety, Generic Biologics & Drug Approvals H.R. 380, "Pharmaceutical Market Access and Drug Safety Act of 2007" - Importation. S.251, Pharmaceutical Market Access & Drug Safety Act of 2007" - Importation. S.242, "Pharmaceutical Market Access & Drug Safety Act of 2007" H.R. 1561, Enhancing Drug Safety and Innovation Act of 2007 H.R. 3610 Food and Drug Import Safety Act of 2007 S. 4, Improving America's Security Act of 2007, cargo-screening provision
Client expense: $658,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2008 · fourth_quarter · Pharmacy
PHA (Pharmacy) (Legislative): H.R. 971: Community Pharmacy Fairness Act (Weiner); H.R. 1038: Access to Life-Saving Medicine Act (Waxman); H.R. 5629: Pathway for Biosimilars Act (Eshoo-Barton) (continued) PHA (Legislative) (continued): S. 316: Preserve Access to Affordable Generics Act (Kohl); S. 623: Access to Life-Saving Medicine Act (Schumer); S. 885: Community Pharmacy Fairness Act (Isakson); S. 1505: Affordable Biologics for Consumers Act (Gregg); S. 1695: Biologics Price Competition and Innovation Act (Kennedy) PHA (Regulatory): Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to access for investigational drugs; and issues related to electronic prescribing requirements; issues relating to e-prescribing of DEA controlled substances.
Client expense: $2,240,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Personnel Management (OPM), SENATE, Social Security Administration (SSA), Treasury, Dept of
Vaccine Injury Compensation Program Follow developments within the Administration relating to global health policies concerning U.S. government participation in WHO and UN health initiatives; international public health issues; U.S. sanctions policies; international vaccine issues; vaccine policy at the Pan American Health Organization; HR 3610 HR 5629 Childhood immunizations Dietary supplement issues Implementation issues concerning P.L. 108-173 - The Medicare Prescription Drug, Improvement and Modernization Act of 2003 Drug compounding Alzheimer's care Comparative effectiveness - S.3408 - Comparative Effectiveness Research Act of 2008 S. 1695 Biologics Price Competition and Innovation Act of 2007 H.R. 1812 - Menopausal Hormone Replacement Therapies and Alternative Treatments and Fairness Act Pediatric Studies and Trials Drug Safety/Clinical Trials H.R. 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007 S. 623/HR 1038 - Access to Life Saving Medicine Act, Follow-on Biologics S. 1505 - Affordable Biologics for Consumers Act H.R. 3610 - Food and Drug Import Safety Act of 2007 S.2029 - Vaccine Safety and Payment Health care issues Drug approvals Reimbursement rates S. 334 The Healthy Americans Act H.Con.Res. 342 (BHRT) FDA Pre-emption S.3613, H.R. 7114 - Independence at Home Act S.3409-Drug and Device Accountability Act of 2008 Follow-on biologics Drug importation and counterfeiting Drug advertising Comparative effectiveness Physician payment disclosure Hormone replacement therapies Chronic Illness International public health issues International vaccine issues
Client expense: $1,047,210 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
H.R. 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007 S. 623/HR 1038 - Access to Life-Saving Medicine Act, Follow-on Biologics S.1695 - Biologics Price Competition and Innovation Act of 2007 S.1505- Affordable Biologics for Consumers Act H.R. 5629 - "Pathway for Biosimilars Act" H.R. 3610 - Food and Drug Import Safety Act of 2007 S.3409 - Drug and Device Accountability Act of 2008 Biosimilars Drug Safety Prescription Drug Importation Import Safety Compoundin
Client expense: $1,047,210 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2008 · fourth_quarter · Pharmacy
Access to Life-Saving Medicine Act (H.R. 1038 & S. 623), Affordable Biologics for Consumers Act (S. 1505), Biologics Price Competition and Innovation Act of 2007 (S. 1695), Consumer Food Safety Act of 2008 (H.R. 3624), Fair Prescription Drug Competition Act (H.R. 806 & S. 438), Food and Drug Import Safety Act of 2007 (H.R. 3610, The Pathway for Biologics Act (H.R. 5629), The Patient Protection and Innovative Biologic Medicines Act (H.R. 1956).
Client expense: Not reported · Firm income: $40,000
Government targets: Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
2008 · fourth_quarter · Pharmacy
S877: CONTROLLING THE ABUSE OF PRESCRIPTIONS ACT OF 2007; DRUG IMPORTATION ASPECTS HR4911: HUMAN GROWTH HORMONE RESTRICTION ACT OF 2007; ALL PROVISIONS OF BILL HR1038: ACCESS TO LIFE SAVING MEDICINE ACT; FOLLOW-ON BIOLOGICS PROVISIONS HR1956: PATIENT PROTECTION AND INNOVATIVE BIOLOGIC MEDICINES ACT OF 2007; FOLLOW ON BIOLOGICS HR5629: PATHWAY FOR BIOSIMILAR ACT; ALL PROVISIONS OF BILL S1505: AFFORDABLE BIOLOGICS FOR CONSUMERS ACT; FOLLOW ON BIOLOGICS S1695: BIOLOGICS PRICE COMPETITION AND INNOVATION ACT OF 2007; FOLLOW ON BIOLOGICS S623: ACCESS TO LIFE-SAVING MEDICINE ACT; FOLLOW ON BIOLOGICS HR5839: SAFEGUARDING AMERICA'S PHARMACEUTICALS ACT OF 2008; ALL PROVISIONS OF BILL HR6752/S3396: INDEPENDENT DRUG EDUCATION AND OUTREACH ACT OF 2008; ALL PROVISIONS OF BILL
Client expense: $500,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Pharmacy
H. R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H. R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics H. R. 5629, Pathway for Biosimilars Act S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 623, Access to Life-Saving Medicine Act, follow-on biologics
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2008 · fourth_quarter · Pharmacy
H. R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H. R. 1561, Enhancing Drug Safety and Innovation Act of 2007, drug safety provisions H. R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics S. 1505, Affordable Biologics for Consumers Act, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 596, Safe Internet Pharmacy Act of 2007, clinical trials/drug safety provisions S. 623, Access to Life-Saving Medicine Act, follow-on biologics Drug importation H.R. 5629, Pathway for Biosimilars Act H.R. 5839, Safeguarding America's Pharmaceuticals Act of 2008
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2008 · fourth_quarter · Pharmacy
S. 877, Controlling the Abuse of Prescriptions Act of 2007 Drug importation H. R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H. R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics H. R. 5629, Pathway for Biosimilars Act S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 623, Access to Life-Saving Medicine Act, follow-on biologics
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE
2008 · fourth_quarter · Pharmacy
H. R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H. R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics H. R. 5629, Pathway for Biosimilars Act H. R. 4911, Human Growth Hormone Restriction Act of 2007 S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 596, Safe Internet Pharmacy Act of 2007, clinical trials/drug safety provisions S. 623, Access to Life-Saving Medicine Act, follow-on biologics S. 877, Controlling Abuse of Prescription Drugs Act of 2007 H.R. 5839, Safeguarding America's Pharmaceuticals Act
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE
2008 · fourth_quarter · Pharmacy
H. R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H. R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics H. R. 5629, Pathway for Biosimilars Act S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 623, Access to Life-Saving Medicine Act, follow-on biologics S. 877, Controlling the Abuse of Prescriptions Act of 2007
Client expense: Not reported · Firm income: $50,000
Government targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2008 · fourth_quarter · Pharmacy
H. R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H. R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics H. R. 5629, Pathway for Biosimilars Act S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 4, Improving America's Security Act of 2007, cargo-screening provision S. 596, Safe Internet Pharmacy Act of 2007, clinical trials/drug safety provisions S. 623, Access to Life-Saving Medicine Act, follow-on biologics Neglected Disease Issues
Client expense: Not reported · Firm income: $100,000
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2008 · fourth_quarter · Pharmacy
HR 1038, Access to Life-Saving Medicines Act, follow-on biologics HR 1561, Enhancing Drug Safety and Innovation Act of 2007 HR 1956, Patient Protection and Innovative Biologics Medicines Act of 2007, follow-on biologics S 1505, Affordable Biologics for Consumers Act, follow-on biologics S 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S 2029, Physician Payments Sunshine Act of 2007 S 595, Safe Internet Pharmacy Act of 2007 S 623, Access to Life-Saving Medicines Act, follow-on biologics HR 5629, Pathway for Biosimilars Act HR 5839, Safeguarding America's Pharmaceuticals Act
Client expense: $580,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2008 · fourth_quarter · Pharmacy
H.R.1038, Access to Life-Saving Medicine Act, follow-on biologics H.R.1561, Enhancing Drug Safety and Innovation Act of 2007 H.R.1956, Patient Protection and Innovative Biologics Medicines Act of 2007, follow-on biologics S.1505, Affordable Biologics for Consumers Act, follow-on biologics S.1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S.596, Safe Internet Pharmacy Act of 2007 S. 623, Acces to Life-Saving Medicine Act, follow-on biologics H.R.5629, Pathway for Biosimilars Act H.R.5839, Safeguarding America's Pharmaceuticals Act Drug Imporation
Client expense: $440,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2008 · fourth_quarter · Medical/Disease Research/Clinical Labs
Support efforts to obtain approval of at least one more compendia by the Department of Health and Human Services for use in Medicare reimbursement decisions for cancer medications. S. 1505 - Affordable Biologics for Consumers Act S. 1695 Biologics Price Competition and Innovation Act of 2007, support enactment and follow-on Biologics legislation with amendments that strengthen FDA pathway and provide data exclusivity. H.R. 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Health Issues
H.R. 4703, S. 2467, H.R. 4991 - Vaccine Shortage Preparedness Act of 2008 S. 2464, H.R. 4992, H.R. 4704 - A bill to amend title XVIII of the Social Security Act to provide for coverage of federally recommended vaccines under Medicare, Part B S. 2465, H.R. 4702, H.R. 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program S. 2467, H.R. 4703, H.R. 4991 - a bill to amend the Social Security Act, the Federal Food, Drug and Cosmetic Act, and the Public Health Service Act to ensure a sufficient supply of vaccines and for other purposes Opposed efforts to amend the Federal Food, Drug and Cosmetic Act with respect to the sale of prescription drugs through the internet, and for other purposes. Lobbied to ensure that the Internet would not be used to import counterfeit and defective medical products H.R. 4705 - Vaccines for the Uninsured Adult Act of 2008 S. 3678 - Pandemic All Hazards Preparedness Act (Biodefense) S. 1505 - Affordable Biologics for Consumers Act S. 1695 Biologics Price Competition and Innovation Act of 2007, support enactment and follow-on Biologics legislation with amendments that strengthen FDA pathway and provide data exclusivity H.R. 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007 H.R. 1038 Access to Life-Saving Medicine Act S. 623 - Access to Life-Saving Medicine Act General matters related to vaccine industry stability, pandemic preparedness, avian influenza
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Health Issues
H.R. 1956 Patient Protection and Innovative Biologic Medicines Act of 2007 S. 1505 Affordable Biologics for Consumers Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Pharmacy
S. 623 - Access to Life-Saving Medicine Act S. 438 - Fair Prescription Drug Competition Act H.R. 806 - Fair Prescription Drug Competition Act H.R. 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007 H.R. 5629 - The Pathway for Biologics Act H.R. 1038 - Access to Life-Saving Medicine Act S. 1505 - Affordable Biologics for Consumers Act S. 1695 - Biologics Price Competition and Innovation Act of 2007 H.R. 3610 - Food and Drug Import Safety Act of 2007 S.28 - To amend title XVIII of the Social Security Act to require the use of generic drugs under the Medicare part D prescription drug program when available unless the brand name drug is determined to be medically necessary. H.R. 3624 - Consumer Food Safety Act of 2007
Client expense: $510,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2008 · fourth_quarter · Medical/Disease Research/Clinical Labs
S. 623 Access to Lifesaving Medicine Act H.R. 1038 Access to Lifesaving Medicine Act H.R. 1956 Patient Protection and Innovative Biologic Medicine Act of 2007 S. 1695 Biologics Price Competition and Innovation Act of 2007 S. 1505 Affordable Biologics for Consumer Act H.R. 5629 Pathway for Biosimilars Act
Client expense: $2,000,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2008 · fourth_quarter · Pharmacy
Pharmacy issues - S 623, Access to Life-Saving Medicine Act; HR 1038, Access to Life-Saving Medicine Act; S 1505, Affordable Biologics for Consumers Act; S 316, Preserve Access to Affordable Generics Act; S 1695, Biologics Price Competition and Innovation Act of 2007; HR 971, Community Pharmacy Fairness Act of 2007; S 885, Community Pharmacy Fairness Act of 2007; HR 5629, Pathway for Biosimilars Act.
Client expense: Not reported · Firm income: $100,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Pharmacy
H.R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H. R. 1956, Patient Protection Innovative Biologic Medicine Act of 2007, follow-on biologics H.R. 5629, Pathway for Biosimilars Act S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 623, Access to Life-Saving Medicine Act, follow-on biologics
Client expense: $340,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE